Related Experiment Videos

Sequelae of breast irradiation

R Lipsztein, J F Dalton, W D Bloomer

|June 28, 1985

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

British journal of cancer·2010

Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II.

Oncology research·2007

Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.

Oncology research·2003

Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.

Cancer chemotherapy and pharmacology·2002

Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.

International journal of cancer·2001

In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).

In vivo (Athens, Greece)·2001

See all related articles